Auriga
Auriga USA is a research and trading platform that focuses on growth sectors within the Health Care and Technology verticals. We operate out of our main office in New York City, and also have satellite offices in Boston, San Francisco, Philadelphia, San Diego, and Washington D.C. This regional network helps us to keep abreast of key corporate developments, enhance client relationships, and provide more efficient product distribution to meet clients' investment needs. The firm is committed to providing our clients with critical information flow, investment ideas, and access to industry experts.
View Older Stories View More Recent Stories
-
Auriga Maintains a 'Hold' on NetLogic (NETL); Acquisition Almost a Done Deal
-
Auriga Maintains a 'Buy' on Broadcom (BRCM); NetLogic Deal Strategic but too Expensive and Likely the Wrong Choice
-
Auriga Upgrades SunPower (SPWRA) to Buy; Now That's a Class Act!
-
Auriga Maintains a 'Buy' on Xilinx (XLNX); Near-Term Risk; 28nm to Drive Long-Term Growth
-
Auriga Maintains a 'Buy' on Altera (ALTR); Near term Weakness but Longer Term Trends Intact
-
Auriga Upgrades Myriad Genetics (MYGN) to Buy; Patience Will Be Rewarded
-
Unusual 11 Mid-Day Movers 09/08: (CALP) (CWTR) (PMIC) Higher; (GIII) (TITN) (FIO) Lower
-
Notable Analyst Rating Changes 09/08: (CSCO) (SWY) (STO) Upgraded; (KWK) (AEP) (HSP) Downgraded
-
Auriga Upgrades Juniper Networks (JNPR) to Buy
-
Auriga Upgrades Cisco (CSCO) to Buy
-
Auriga Starts OCZ Technology Group (OCZ) at Hold; Not A Likely Winner in High Growth SSD Space - Price Reflects That View
-
Auriga Starts STEC, Inc. (STEC) at Sell; Enterprise SSD Leader for Now, but Not For Long
-
Auriga Starts Fusion-io (FIO) at Sell; Potentially Great Company, Not So Great Stock
-
Auriga maintains a 'Hold' on athenahealth (ATHN); Vulnerable in a Volatile Market at Current Valuation
-
Auriga Reiterates a 'Buy' on Mettler-Toledo (MTD); Product Innovation, Market Knowledge and Pricing are Key Ingredients
-
Notable Analyst Rating Changes 09/01: (CTSH) (DYN) (ACI) Upgraded; (RPM) (BAH) (GS) Downgraded
-
Auriga Starts HCA Holdings (HCA) at Buy; Concern Over Decline in Medicare Acuity in 2Q Appears Overdone
-
Auriga Reiterates a 'Buy' on EMC (EMC); Shares Look Attractive Given Our Strong Outlook
-
Auriga Reiterates a 'Buy' on Allscripts-Misys Healthcare (MDRX); Going Mobile: iPhone App Reduces Barriers to Physician Adoption
-
Notable Analyst Rating Changes 08/25: (BHP) (FFIV) (AEO) Upgraded; (ECA) (UTHR) (HPQ) Downgraded
-
Auriga Downgrades United Therapeutics Corp. (UTHR) to Hold; FREEDOM-C2 Fails To Hit Primary Endpoint
-
Auriga Starts Universal Health Services (UHS) at Buy
-
Auriga Raises Hewlett-Packard (HPQ) to Buy
-
Notable Analyst Rating Changes 08/22: (SPWRA) (AA) (YGE) Upgraded; (MSFT) (NWSA) (IR) Downgraded
-
Auriga Upgrades SunPower (SPWRA) to Hold; Near-Term Concerns Remain, But 40% Drop to Big to Ignore
-
Auriga Maintains a 'Hold' on Hewlett-Packard (HPQ); What a Mess!
-
Auriga Reiterates a 'Buy' on NetApp (NTAP); Makes EPS Target, but Misses Revenue Goal as Macro Issues are Suddenly Upon Us
-
Auriga Maintains a 'Buy' on Dell (DELL); Margin Expansion Story Intact, but Revenue Outlook Likely a Concern for Investors
-
Auriga Reiterates a 'Buy' on First Solar (FSLR); We Just Said Good Buy; So Why Did Jens Say Good Bye?
-
Auriga Maintains a 'Buy' on MedAssets (MDAS); Lowering Estimates and Price Target
-
Auriga Maintains a 'Hold' on Hewlett-Packard (HPQ); Expect Solid Quarter from HP, but Remain Wary of the Value Trap
-
Auriga Upgrades Waters Corp. (WAT) to Buy; Calmer Waters Ahead? We Think So
-
Auriga Reiterates a 'Buy' on eResearch Technology (ERT); A "Three-Legged Stool" with a Strong Path to Growth
-
Auriga Reiterates a 'Buy' on Dell (DELL); Looks Like A Good Safe Haven; Increasing EPS Estimates
-
Auriga Reiterates a 'Buy' on Medidata Solutions (MDSO); A Big Beat, Full Year on Track
-
Auriga Maintains a 'Hold' on Myriad Genetics (MYGN); Q4 Results Review: A Good Performance; Ramping Investment in FY12
-
Auriga Maintains a 'Sell' on SunPower (SPWRA); Cost Structure Has No Easy Fix
-
Auriga Reiterates a 'Buy' on Affymax (AFFY); Hematide at the FDA; Panel and EU Filing on Track for 1H12
-
Notable Analyst Rating Changes 08/08: (KO) (EMC) (TJX) Upgraded; (TXN) (OMX) (FFIV) Downgraded
-
Auriga Upgrades NetApp (NTAP) to Buy; High Quality, Long-Term Growth at Attractive Entry Point
-
Auriga Upgrades EMC (EMC) to Buy; L-T Tech Winner, with Protection During A Downturn
-
Auriga Maintains a 'Hold' on Heartware Intl (HTWR); Germany Comes Roaring Back to Offset Flat U.S.
-
Auriga Reiterates a 'Buy' on Sequenom (SQNM); T-21 Manuscript Submitted; Key Timelines Remain On Track
-
Auriga Reiterates a 'Buy' on First Solar (FSLR); Accumulate Stock Aggressively on Weakness
-
Auriga Maintains a 'Buy' on MEMC Electronic Materials (WFR); Suntech Divorce Settlement Doesn't Count for Earnings
-
Auriga Maintains a 'Buy' on EZchip Semiconductor (EZCH); Strong Results Despite JNPR Headwinds
-
Auriga Maintains a 'Hold' on Thoratec (THOR); 2Q11 Review: Gaining Share in the US? Buys Out Partner, Raises Numbers
-
Notable Analyst Rating Changes 08/03: (MDRX) (GGP) (PCS) Upgraded; (F) (BYD) (BHP) Downgraded
-
Morning Movers 08/03: (CBM) (SIMG) (FIX) (GNET) Higher; (CBR) (KFRC) (EXAM) (KRA) Lower
-
Auriga maintains a 'Buy' on Exact Sciences (EXAS); Timelines on Track; Tweaks Sample Container and Marker Panel

